Detalhe da pesquisa
1.
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.
Int J Mol Sci
; 24(14)2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37511180
2.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 379(4): 341-351, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863979
3.
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Gynecol Oncol
; 159(2): 322-328, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32917410
4.
Rare ovarian tumours. Other treatments for ovarian cancer.
EJC Suppl
; 15: 96-103, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33240448
5.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 20(8): 1124-1135, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257177
6.
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Breast Cancer Res Treat
; 174(3): 693-701, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30607629
7.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Int J Gynecol Cancer
; 29(6): 1050-1056, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31263024
8.
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Lancet Oncol
; 19(6): 812-824, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29706375
9.
Molecular approaches for classifying endometrial carcinoma.
Gynecol Oncol
; 145(1): 200-207, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28040204
10.
TGFß Controls Ovarian Cancer Cell Proliferation.
Int J Mol Sci
; 18(8)2017 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28758950
11.
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Clin Cancer Res
; 30(5): 975-983, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165683
12.
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Clin Cancer Res
; 30(1): 176-186, 2024 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37527007
13.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
J Clin Oncol
; 42(3): 283-299, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864337
14.
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
JAMA Oncol
; 9(11): 1574-1582, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768658
15.
Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey.
Cancers (Basel)
; 15(22)2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001688
16.
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
Cancers (Basel)
; 14(18)2022 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139574
17.
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.
Clin Genitourin Cancer
; 20(4): 388.e1-388.e10, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35428584
18.
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35338084
19.
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
Lung Cancer
; 155: 151-155, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33831732
20.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301809